Biliary-committed progenitor cells (small mouse cholangiocytes; SMCCs) from small bile ducts are more resistant to hepatobiliary injury than large mouse cholangiocytes (LGCCs) from large bile ducts. The definitive endoderm marker, forkhead box A2 (FoxA2), is the key transcriptional factor that regulates cell differentiation and tissue regeneration. Our aim was to characterize the translational role of FoxA2 during cholestatic liver injury. Messenger RNA expression in SMCCs and LGCCs was assessed by polymerase chain reaction (PCR) array analysis. Liver tissues and hepatic stellate cells (HSCs) from primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) patients were tested by real-time PCR for methylation, senescence, and fibrosis markers. Bile duct ligation (BDL) and multidrug resistance protein 2 (MDR2) knockout mice (MDR2 -/-)
T he biliary epithelium is a complex network of interconnected ducts that increase in diameter from small to large bile ducts. (1, 2) The larger portion of the biliary epithelium is lined by mature, cyclic adenosine monophosphate-dependent large cholangiocytes, whereas small (constitutively quiescent) cholangiocytes line small bile ducts. (2) Cholangiocytes are supported on a basement membrane and surrounded by connective tissue, extracellular matrix (ECM), and the peribiliary plexus. (3, 4) These cells are
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specialized to act as an interface within the harsh environment imposed by bile and are morphologically and functionally heterogeneous, but with phenotypic patterns implicating a single maturational lineage. Small and large cholangiocytes have been characterized in the intrahepatic biliary epithelium of rats and mice, and this phenotype is similar in humans as well. (2, 5, 6) It has been proposed that small cholangiocytes contain a population of biliary committed progenitors, showing expression of various biliary progenitor markers, and incorporate into neo-bile ducts at the sites of injury. When large cholangiocytes are damaged, small, Ca 21 dependent cholangiocytes are activated, acquiring phenotypic and functional features of large cholangiocytes and resulting in the repopulation of the injured large bile ducts. (2, 6, 7) The definitive endoderm markers, forkhead box A2 (FoxA2) and SRY (sex determining region Y)-box 17 (Sox17) are key transcriptional factors of cell differentiation. (8, 9) These transcriptional factors are essential for the establishment of developmental competence in the foregut endoderm and initiation of liver specification. Studies have shown that hepatic deletion of FoxA2 causes cholestasis in mice fed a cholic-acidenriched diet. In addition, FoxA2 is down-regulated in human subjects with primary sclerosing cholangitis (PSC) and biliary atresia. (10) Other studies have demonstrated that FoxA2 and Sox17 are down-regulated in the bile-duct-ligated (BDL) mouse model of obstructive cholestasis. (11) Thus, it seems likely that FoxA2 and Sox17 play a major role in patients with chronic cholestatic disorders. The Notch pathway is necessary for specification of the biliary epithelium, and Notch pathway ablation results in failure of hepatoblast specification into cholangiocytes, resulting in bile duct paucity, a characteristic of Alagilles syndrome. (12) Furthermore, ectopic activation of the Notch pathway in fetal hepatoblasts by overexpression of the Notch intracellular domain (NICD) results in hyperarborization of biliary ductules. (12) It has been shown that tumor necrosis factor alpha phosphorylates FoxA2 through IjB kinase alpha. This activates NUMB transcription, which is able to inhibit NICD and prevent further downstream activation. (13) Interestingly, activated Notch signaling can affect expression of both FoxA2 and Sox17, suggesting the functional link among these three multipotent molecules during the differentiation process.
Hepatocyte growth and proliferation may be blocked under the conditions that occur during severe liver injury. When this occurs, cholangiocytes originating from the portal ductules and canals of Herring are able to initiate phenotypical changes allowing them to express hepatocyte-associated transcription factors. (14) Cholangiocytes can also acquire stem cell phenotypes and, in turn, become hepatocytes, restoring liver regeneration when hepatocytes fail to proliferate. (15) However, an alternative interpretation is that regeneration after hepatic injury/partial hepatectomy is derived from liver and biliary stem/progenitor cells. Biliary stem/ progenitor cells are thought to be located within the canals of Hering and have common markers with biliary epithelia. Progenitor cells become more widespread in diseased conditions. (16) Therefore, when hepatocytes fail to proliferate in response to injury, biliary progenitor cells are one of the most important regenerative alternatives. The current study evaluates the possible role of FoxA2-mediated biliary cell restorative therapy during cholestatic liver injury, especially recovery effects on biliary injury and liver fibrosis using BDL animal models (for chronic liver injury) and and multidrug resistance protein 2 (MDR2) knockout (MDR2 -/-) mice that develop periportal fibrosis similar to human PSC. (17) 
Materials and Methods

REAGENTS
All reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise indicated. Antibodies against DNA (cytosine-5)-methyltransferase 1 (DNMT1), DNA (cytosine-5)-methyltransferase 3B (DNMT3B), cadherin 1 (CDH1), cadherin 2 (CDH2), and b-actin were purchased from Cell Signaling Technologies (Danvers, MA). The S100 calcium binding protein A4 (S100A4) primary antibody was purchased from AbCam (Cambridge, MA). All real-time polymerase chain reaction (PCR) primers were obtained from Qiagen (Valencia, CA). Formalin-fixed, paraffin-embedded liver sections (4-5 lm thick) were obtained from 3 patients with PSC and 3 with primary biliary cholangitis (PBC). Five patients had advanced stage (3-4) biliary diseases, (18) and 1 with PBC had an early stage of disease. The six control healthy livers were obtained from patients undergoing resection of liver metastasis (please see Table 1 for patient information).
HUMAN SUBJECTS
ANIMAL MODELS
The Animal Care and Use Committee of Baylor Scott & White approved all the animal protocols used in the study. Male NOD.CB17-Prkdc scid /J (nonobese diabetic/severe combined immunodeficiency; NOD/ SCID) and MDR2 -/-(FVB.129P2) mice (25-30 g; 6-12 weeks of age) were obtained from The Jackson Laboratory (Bar Harbor, ME). 
PURIFIED CHOLANGIOCYTES AND BILIARY CELL LINES
Small and large cholangiocytes were isolated by counterflow elutriation, followed by immunoaffinity separation, (6) using a monoclonal antibody (a gift of Dr. R Faris, Brown University, Providence, RI) against an unidentified antigen expressed by all immortalized normal intrahepatic human (H69, a gift from Dr. G. Gores, Mayo Clinic, Rochester, MN) (19) and murine cholangiocytes. (20) 
ISOLATION OF HEPATIC STELLATE CELLS BY LASER CAPTURE MICRODISSECTION
Frozen liver sections were sectioned with a cryostat and affixed to the membrane side of nuclease and human nucleic acid free 2.0-mm PEN membrane slides (Leica Microsystems, Wetzlar, Germany). A laser capture microdissection (LCM) system (LMD7000; Leica, Buffalo Grove, IL) was used to capture desmin-positive stellate cells and collect them in a PCR tube. Collected cells were used to isolate RNA with the Arcturus Pico Pure RNA Isolation Kit (Applied Biosystems, Foster City, CA), according to the manufacturer's instructions.
STATISTICAL ANALYSIS
All data are expressed as mean 6 SE. The differences between groups were analyzed by Student t test when two groups were analyzed or analysis of variance if more than two groups were analyzed. A P value <0.05 was used to indicate statistically significant differences.
Please see Supporting Materials and Methods for more-detailed information of this section.
Results
CHARACTERIZATION OF BILIARY PROGENITOR PHENOTYPES IN HUMAN AND MURINE SMALL AND LARGE CHOLANGIOCYTES
To demonstrate potential progenitor phenotypes in small and large cholangiocytes in culture, we performed real-time PCR-based superarray analysis. The stem cell PCR array was chosen because it contains 84 key genes related to the identification, growth and differentiation of stem/progenitor cells. Some of these markers are seen frequently in the definitive endoderm (DE) of the developing embryo, and these DE markers could be useful in the identification of progenitor cells located in small cholangiocytes. We found that 7 of the 84 genes were markedly upregulated in small mouse cholangiocyte (SMCC) lines relative to large mouse cholangiocyte (LGCC) lines used as controls; we also detected several down-regulated genes. The two most up-regulated genes were the DE markers, FoxA2 and Sox17 (Fig. 1A) . Upregulation of these genes in mouse and human small and large cholangiocytes was also evaluated by real-time PCR, which confirmed the array data (Fig. 1B) . Activated transforming growth factor beta (TGF-b)-dependent Notch1 and Notch ligand, Jagged 1 (JAG1), was also found in SMCCs, compared to LGCCs, accompanied by a reduced level of E1A binding protein P300 (EP300). Interestingly, several other markers for progenitor cells of the adult epithelium, such as bone morphogenetic protein 1 (BMP1) and aldehyde dehydrogenase 1 (ALDH1), were also overexpressed in mouse and human SMCCs.
TGF-b AND ACTIVIN A PROMOTE HUMAN LIVER PROGENITOR CELLS TO ACQUIRE SMALL BILIARY PHENOTYPES
DE has been successfully derived in vitro from mouse embryonic stem cells (ESCs) using culture conditions of low serum and high concentrations of Activin A. Under these conditions, it has been shown that TGF-b improves efficiency of Activin A-induced DE differentiation from human ESCs. (21) We hypothesized that TGF-b improves efficiency of Activin A-induced biliary differentiation in human liver progenitor cells (LPCs). To test this hypothesis, we treated human LPCs with Activin A in the presence or absence of TGF-b in William's E medium for 7 days on plates coated with Matrigel, which has been shown to promote differentiation of hepatic progenitor cells to cholangiocytes. After treatment in William's E medium for 5 days, cells were analyzed for expression of FoxA2 and Sox17. Immunofluorescent staining revealed that approximately 80% of cells treated with Activin A and TGF-b expressed FoxA2 or Sox17, whereas only around 40% of cells were FoxA2 or Sox17 positive when treated with Activin A alone (Fig. 1C) . TGF-b alone did not affect biliary differentiation. Real-time PCR confirmed that expression of FoxA2 and Sox17 was significantly increased upon cotreatment with both Activin A and TGF-b, whereas addition of TGF-b alone did not induce biliary differentiation from human LPCs. Together, these preliminary data indicate that TGF-b augments human LPC-derived SMCC formation by acting synergistically with Activin A.
Given that TGF-b is a well-known mesenchymalto-epithelial transition (MET) inhibitor, we aimed to demonstrate TGF-b activation of the mesenchymal markers, S100A4 and Vimentin, in small and large cholangiocytes in vitro. TGF-b (10 ng/mL) induced significant cell differentiation after 7 days of incubation, as measured by incorporation of S100A4 and Vimentin protein expression, as well as by the epithelial marker, E-Cadherin (CDH2), to the mesenchymal marker, N-Cadherin (CDH1), switch and antiapoptotic properties in human small and large cholangiocytes ( Fig. 1D and Supporting Figs. S1A and S2A). Analysis of cytokeratin-19 (CK-19) levels by real-time PCR showed similar levels of CK-19 in H69 LGCCs compared to SMCCs (Fig. 1E) . LGCCs is shown (n 5 3). Expression of a panel of diverse epigenetic-associated genes was evaluated by real-time PCR using the Mouse Epigenetic Chromatin Modification Enzymes PCR Array from SABioscience, Frederick, MD. Gene expression relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was plotted as the Volcano Plots, depicting the relative expression levels (Log 2) for selected genes in SMCCs versus control LGCC panels (left). Relative expression levels and P values for each gene in the related samples were also plotted against each other in the scatter plot (right). DNMT3B and DNMT3A were the most down-regulated genes among the five epigenetic signaling pathways in cholangiocytes. (B) Real-time PCR confirmed the reduced mRNA expression of DNMT3B and DNMT3A in cultured SMCCs, isolated SMCCs from BDL mice liver, and small human cholangiocytes (H69-SM), compared to respective controls. The percentages shown represent the mean value (relative to control) normalized with GAPDH from four independent experiments. (C) Analysis of the promoter region using MethPrimer software revealed the presence of several CpG islands 2,000 bp upstream of the 5 0 -region of the FoxA2 and Sox17 sequence. (D) Small and large cholangiocytes were treated with 10 lM of 5-Aza-CdR or diluent control for 72 hours. Expressions of FoxA2, Sox17, and Notch1 were assessed by western blotting analysis. 5-Aza-CdR increased FoxA2 and Sox17 expression in LGCCs, but not SMCCs. Representative immunoblottings are shown on the top right along with quantitative data that show the mean 6 SE from four separate blottings of independent experiments on bottom panel. *P < 0.05 relative to control; # P < 0.05 relative to SMCCs. (E) DNMT3A was overexpressed in SMCCs. Top panel: Cells were harvested with trypsin, stained with trypan blue, and cell size was measured compared to control as a percentage with the control set at 0. *P < 0.05 compared to control. Bottom panel: RNA was extracted and markers of small and large cholangiocytes were measured with quantitative PCR (qPCR). *P < 0.05 compared to control. (F) DNMT3A was overexpressed in SMCCs, RNA was extracted, and DE markers were measured with qPCR. *P < 0.05 compared to control. Abbreviations: Con, control; Ct, threshold cycle; H1HR, H1 histamine receptor; OE, overexpressed.
FoxA2 AND Sox17 EXPRESSION IS EPIGENETICALLY REGULATED
To evaluate the potential epigenetic mechanisms by which the expression of FoxA2 and Sox17 is deregulated in small cholangiocyte/biliary progenitors, we performed a real-time PCR-based superarray analysis. The epigenetic chromatin modification enzymes PCR array was chosen because it contains 84 key genes encoding enzymes known or predicted to modify genomic DNA and histones to regulate chromatin accessibility and gene expression. The two most downregulated genes detected by PCR array in SMCCs relative to LGCCs were DNMT3B and DNMT3A ( Fig. 2A) . Down-regulation of these genes was confirmed by real-time PCR (Fig. 2B) . Additionally, analysis of the promoter regions of FoxA2 and Sox17 by the MethPrimer program (22) revealed the presence of several CpG islands 2,000 base pairs (bp) upstream of the 5 0 -coding regions, which are commonly modified by epigenetic regulation (Fig. 2C) . To evaluate the direct relationship between methylation and FoxA2 or Sox17 expression in cholangiocytes, the methylation inhibitor, 5-aza-2 0 deoxy-cytidine (5-Aza-CdR), was used to treat SMCCs or LGCC in vitro before evaluating FoxA2 and Sox17 expression. The marked increases of FoxA2 and Sox17 were noted in LGCCs (but not SMCCs), compared to controls, after 5-AzaCdR treatment (Fig. 2D) . Using a methylationspecific PCR assay, we found that the FoxA2 promoter was hypomethylated in SMCCs in culture (Supporting Fig. S1B ) as well as in isolated small cholangiocytes from livers from BDL mice (Supporting Fig. S1C ). These results suggest that expression of FoxA2 and Sox17 may be potentially regulated by modulation of promoter methylation. Of note, histone acetylation has been shown to activate expression of FoxA2 and Sox17 during the early stage of hepatocyte differentiation. (23) To evaluate the direct relationship between DNMT3A and cell size, DNMT3A was overexpressed in SMCCs. Overexpression of DNMT3A showed an increase in overall cell size (Fig. 2E, top) as well as increased levels of the LGCC markers, cystic fibrosis transmembrane conductance regulator (CFTR), secretin (Sec), and secretin receptor (SR), (5) (Fig. 2E , bottom), indicating the ability of DNMT3A to influence cell size through possible down-regulation of DE markers. Additionally, the direct relationship between FoxA2 and Sox17 was analyzed by real-time PCR. Overexpression of DNMT3A showed reduced levels of FoxA2, Sox17, Notch1, and BMP1 ( , secretion levels of soluble TGF-b were significantly up-regulated (Fig. 3A) . To determine the mechanisms of TGF-b messenger RNA (mRNA) alterations and their effects on modulating target protein expression in vivo, we compared BMP1/ FoxA2/Notch1/Sox17 expression in tissue homogenates and isolated cholangiocytes from mouse liver. Expression of BMP1/FoxA2/Notch1/Sox17 protein and mRNA was significantly decreased in BDL and MDR2 -/-mouse liver and isolated cholangiocytes, compared to normal controls (Fig. 3B,C) , which suggests alternate TGF-b-regulated microRNA/mRNA expression patterns in different liver cell types. To explore this further, we overexpressed TGF-b in SMCCs and analyzed levels of DE markers. Unlike in total liver or isolated pooled (that include both small and large) cholangiocytes, FoxA2 was increased in SMCCs (Fig. 3D) , indicating that up-regulation of TGF-b leads to up-regulation of FoxA2, which may indicate activation of the progenitor cells contained in SMCCs. Activated definitive endoderm differentiation markers FoxA2 and Sox17 were observed in small bile ducts after cholestatic liver injury in BDL and MDR2 -/-(Supporting Fig. S2B ). To further assess the extent of fibrosis/cirrhosis in BDL/MDR2 -/-mouse liver, Sirius Red staining was performed on liver sections from both animal models (Fig. 3E,F) . Control mice had a normal distribution of collagen, whereas those with BDL and MDR2 -/-demonstrated obvious signs of fibrosis. Mice with BDL injury demonstrated bridging fibrosis and those with MDR2 -/-had diffuse collagen deposition, suggesting severe liver fibrosis in both models of cholestatic liver injury.
FoxA2 IS DOWN-REGULATED IN HUMAN CHOLESTATIC LIVERS
We have demonstrated that TGF-b levels are elevated in patients with PSC and PBC as well as the levels of fibrotic genes, such as collagen A1, fibronectin, and alpha-smooth muscle actin (a-SMA; Supporting Fig. S1D-F) . Next, we aimed to determine whether expression of DE and epigenetic markers is altered under cholestatic conditions in humans. FoxA2 mRNA levels were virtually undetectable in patients with PSC (Fig. 4A, left) , as well as in those with PBC, with a reduction in two of three livers measured (Fig.  4A, right) . Meanwhile, expression of Sox17 was significantly increased in PSC livers, but reduced in PBC livers (Fig. 4B,C) , suggesting different pathological mechanisms of this DE marker during human cholestatic liver disorders. In both PSC and PBC patients, Notch-1 and BMP-1 levels were increased compared to normal patients (Fig. 4D,E) . These results show that certain progenitor markers are indeed altered frequently in human PSC and PBC. To further verify the upstream mechanisms of FoxA2 regulation, we performed real-time PCR studies to detect mRNA expression of the enzymes that catalyze the methyl-transfer reaction, the DNMTs. Both DNMT1 and DNMT3B were significantly up-regulated in PSC and PBC livers (Fig. 4B,C) , which is consistent with our cell-culture studies (Fig. 2B,D) and implies the potential epigenetic regulatory mechanisms of FoxA2 during development and progression of human PSC and PBC. Thus, -/-mice liver with the respective controls (E,F). Significantly increased intensity of liver fibrosis was confirmed in both models by enhanced Sirius Red expression (n 5 5). *P < 0.05 versus normal or WT controls. Abbreviations: Con, control; ELISA, enzymelinked immunosorbent assay; NR, nuclear receptor; OE, overexpressed; WT, wild type. cholestatic liver injury of differing etiologies causes down-regulation of FoxA2 in humans, which may occur through the epigenetic regulation mechanisms, and, together with our findings, suggests that low FoxA2 levels exacerbate fibrotic injury to the liver.
ROLE OF SMALL CHOLANGIOCYTE THERAPY IN AMELIORATING BDL-INDUCED BILIARY DAMAGE AND LIVER FIBROSIS
Because small cholangiocytes may possibly contain a compartment of progenitor cells for repairing the biliary epithelium, we performed studies to determine whether suitable biliary support using transplanted small cholangiocytes would permit hepatic repair and regrowth of the damaged liver. Because cholangiocytes can be transplanted in large numbers in the peritoneal cavity, readily equaling or exceeding those in the liver, we labeled cultured SMCCs and LGCCs with a red fluorescent marker (PKH26), suspended them in ECM, and injected them into BDL mice 1 and 3 days postsurgery. Translocation of engrafted biliary progenitors/cholangiocytes in liver was detected in liver sections after cell therapy (Fig. 5A) . Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in NOD/SCID mice engrafted with SMCCs and liver stem cells (3 3 10 6 , intraperitoneally) showed significant changes compared to vehicletreated mice (Supporting Fig. S1D ; n 5 5), along with significantly improved TGF-b levels in bile (Fig. 5B) .
FIG. 4.
Enhanced fibrosis markers along with reduced FoxA2 expression in human PSC/PBC liver. (A-E) Altered FoxA2, Sox17, Notch1, and BMP-1 expression along with enhanced DNMTs in human PSC and PBC liver tissues. Total RNA was isolated from human liver from normal controls or patients with PSC/PBC. Real-time PCR analysis was performed, and the ratio of specific mRNAs to GAPDH mRNA expression in human liver samples was determined. PCR products were also verified by 1.8% agarose gel electrophoresis. FoxA2 was significantly reduced in five among six PSC/PBC livers relative to normal controls (A). Meanwhile, expression of Sox17 was only silenced in PBC liver tissues, but increased in PSCs (B,C). DNA methylation enzymes DNMT1 and DNMT3B were also increased in both PSC and PBC livers, suggesting the potential hypermethylation mechanisms of FoxA2 gene during PSC/PBC development. Additionally, both Notch-1 and BMP-1 were significantly reduced in PBC and PSC livers compare to controls (D,E). Data represent mean 6 SE from liver samples from 3 PSC or 3 PBC patients relative to 3 normal controls with three separate experiments. *P < 0.05 relative to normal controls. Abbreviations: Con, control; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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The activated definitive endoderm differentiation marker, FoxA2, was observed in BDL mice liver after cholestatic injury coupled with SMCC cell therapy (Fig. 5C ). Furthermore, decreased Sirius Red staining (Fig. 5D,E) , along with altered remodeling properties, such as activation of matrix metalloproteinase (MMP)-9/MMP-2 and silencing of tissue inhibitor of metalloproteinases-3 (TIMP-3), as well as enhanced expression of remodeling protein a-SMA (Supporting Fig. S2D ,E), were observed in BDL mice liver recovered after SMCC engraft, suggesting that remodeling enzymes and proteins are important mediators for SMCC-mediated recovery of cholestatic liver injury and liver fibrosis. Additionally, we examined total liver tissue for markers of cholangiocytes, and we observed up-regulation of the large cholangiocyte marker in BDL mice treated with either small or large cholangiocytes. BDL mice treated with LGCCs showed upregulation of secretin and secretin receptor (Fig. 5F ), which is expected because of the large influx of
LGCCs. Additionally, we observed a decrease in the large cholangiocyte markers, anion exchanger 2 (AE2) and secretin receptor in SMCC-treated cholangiocytes, most likely attributed to the significant increase in small cholangiocytes.
POTENTIAL MOLECULAR MECHANISMS BY WHICH BILIARY CELL THERAPY IMPROVES BDL-INDUCED BILIARY DAMAGE AND LIVER FIBROSIS
To examine the molecular mechanisms by which biliary cell reversed BDL-induced hepatobiliary damages, we used the Mouse Fibrosis PCR array (PAMM-120ZA; Qiagen) and combined it with PCR of inflammation-and stem-cell-and development-related genes to evaluate mechanisms related to liver fibrosis, inflammation, and stem cell signaling pathways. a-SMA, MMP-8, and MMP-9 were the most down-regulated genes among the fibrotic signaling pathways in cholestatic liver (BDL) coupled with SMCC therapy, compared to those treated with LGCC therapy (Fig. 6A) . Ingenuity Pathway Analysis (IPA) was performed to ascertain the cellular context of the differentially expressed genes related to SMCC-mediated liver repair. Pathway analysis indicated that the hepatic cellular senescence pathway was the most inhibited through FoxA2-related signaling mechanisms (Fig. 6B ). Further analysis with IPA uncovered several differentially regulated cellular senescence gene alterations following small cholangiocyte cell therapy. Several of these genes are regulated by FoxA2, including cyclin-dependent kinase inhibitor 2A (p16), plasminogen activator inhibitor-1 (PAI-1), chemokine (C-C motif) ligand 2 (CCL2), and early growth response protein 1 (EGR1). To evaluate overall cellular senescence in SMCC therapy animals, liver sections were stained with senescenceassociated beta-galactosidase (SA-b-Gal; Fig. 6C ) as described. SMCC therapy significantly reduced cellular senescence post-BDL as quantified by SA-b-Gal staining (Fig. 6C ) and fluorometric detection (Fig. 6E, left) . Total liver isolates were used to evaluate levels of senescence markers, which revealed decreased levels of p16, PAI-1, EGR-1, and CCL2 in SMCC-treated BDL mice compared to BDL mice treated with vehicle (ECM; Fig. 6F, left) . To evaluate the direct relationship between cellular senescence and FoxA2, the senescence gene, p16, was overexpressed in SMCCs, which led to a decrease in FoxA2 levels (Fig. 6D) . This indicates a possible mechanism where biliary damage induces senescence and overexpression of senescence genes suppresses repair mechanisms.
We then aimed to evaluate the mechanisms by which SMCCs are able to suppress biliary fibrosis. Because stellate cells are implicated in liver fibrosis and cellular senescence is highly up-regulated in total liver, we evaluated stellate cells from livers of SMCC therapy mice for senescent markers. We found enhanced expression of the cellular senescence markers, p16 and EGR1, in isolated mouse hepatic stellate cells (HSCs) by LCM (Fig. 7A,B) , as well as up-regulation of cellular senescence, as measured by fluorometric analysis (Fig. 6E, right) , suggesting that senescence of activated stellate cells limits liver fibrosis during the FoxA2-mediated cell therapy process. We additionally isolated stellate cells from PSC patients with LCM and observed decreased levels of the senescence gene, PAI-1, and increased levels of the inflammatory gene, interleukin-8 (IL-8; Fig. 7C ), indicating that stellate cells are active in this disease model.
To evaluate the interactions between cholangiocytes and stellate cells, we used isolated cholangiocytes from our cell therapy BDL-treated animals to extract supernatants, which contain the cytokines, extracellular vesicles, and other molecules that are secreted by cholangiocytes and treated cultured stellate cells with these supernatants. After a 48-hour incubation, the stellate cells treated with SMCC-BDL cholangiocyte supernatants showed decreased levels of the inflammatory markers, CCL2 and IL-8, and increased levels of p16 (Fig. 6F, right) , indicating that the ability of molecules or vesicles secreted by cholangiocytes is able to affect inflammation and senescence in HSCs. This ability to influence these cells most likely alters the activity of HSCs and thus ameliorates the fibrosis observed in SMCC-treated BDL mice.
Discussion
The maintenance of homeostasis of the biliary epithelium is critical for prevention and recovery from hepatobiliary damage that occurs during the pathogenesis of chronic cholestatic liver diseases, such as PBC and PSC. Although the functional role for biliary progenitor cells in liver regeneration has been proposed, the molecular mechanisms by which transcriptional factors, such as FoxA2, modulate hepatobiliary regrowth and hepatic repair are unknown. We identified definitive endoderm markers, including FoxA2, Sox17, as well as BMP1, that are up-regulated in SMCCs, compared to control LGCCs, by PCR array analysis. FoxA2 was also more enhanced in murine liver progenitor cells, compared to SMCCs and LGCCs, and reduced in liver tissues from human PSC/PBC patients. As in PBC and PSC, reduced FoxA2 expression was observed in murine small bile ducts in BDL and MDR2 -/-mouse liver, suggesting that it is an important mediator of biliary injury and recovery. Translocation of engrafted biliary progenitors/cholangiocytes into the liver after intraperitoneal injection The expression of a panel of diverse fibrosisassociated genes was evaluated by real-time PCR using Mice Fibrosis PCR Array from SABioscience, Frederick, MD. Gene expression relative to glyceraldehyde-3-phosphate dehydrogenase was plotted as the Volcano Plots, depicting the relative expression levels (log 10 ) for selected genes in BDL1Small versus BDL1Large control panels. a-SMA, MMP-2 and MMP-9 are the most downregulated genes among the fibrotic signaling pathways in small cholangiocytes cell therapy after BDL injury. (B,C,E,F) Altered cellular senescence after small cholangiocytes cell therapy. Panel B presents Ingenuity Pathway Analysis (IPA) of differentially regulated gene network after small cholangiocytes cell therapy. IPA was performed to understand the cellular context of the differentially expressed genes related to the recovery effects. Several genes implicated in cellular senescence are regulated by FoxA2, including p16 (CDKN2A), PAI-1 (SERPINE1), CCL2 and EGR1. Liver sections are stained with SA-b-Gal (Panel C) as described to reveal cellular senescence in BDL mice 1small relative to 1ECM and 1Large controls. Small cholangiocytes cell therapy significantly reduced cellular senescence after BDL as quantified by SA-b-Gal staining (Panel C) and flurometric detections (Panel E, left), whereas the enhanced cellular senescence in isolated hepatic stellate cells by LCM was observed (Panel E. right). The alterations of cellular senescence markers p16, PAI-1, CCL2 and EGR1 after small cholangiocytes therapy in BDL mice liver were also verified (Panel F, left). *P < 0.05 versus normal controls.
# P < 0.05 versus BDL1ECM controls. (D) p16 overexpression was performed in SMCCs, RNA was extracted and FoxA2 levels were measured with quantitative PCR (qPCR). *P < 0.05 versus control. (F) Cholangiocyte supernatants derived from BDL mice treated with ECM, SMCC or LGCC were used to treat cultured stellate cells and inflammatory markers (CCL2 and IL-8) and a senescence marker (p16) were measured with qPCR. *P < 0.05 versus basal; # P < 0.05 versus BDL1ECM. Abbreviations: ACTA2, actin, alpha 2, smooth muscle, aorta; Ct, threshold cycle; INHBE, inhibin beta E; LOX, lysyl oxidase; OE, overexpressed; RFU, relative fluorescence units; VEGFA, vascular endothelial growth factor A.
was confirmed by PKH26 red fluorescent labeling detected within the liver following cell therapy. Serum ALT and AST levels in NOD/SCID mice engrafted with SMCCs showed significant changes compared to vehicle-treated mice, along with significantly improved liver fibrosis. Enhanced expression of the DE differentiation marker, FoxA2, was observed in BDL mice liver after SMCC cell therapy, along with reduced hepatic/enhanced hepatic stellate cellular senescence. Overexpression of FoxA2 in LGCCs and subsequent intraperitoneal injection into BDL mice showed similar reductions in biliary injury to that observed with SMCC cell therapy. Identification of FoxA2 as an important transcriptional regulator of recovering events FIG. 7 . Alterations of cellular senescence markers in mouse HSCs isolated by LCM. Schematic representation of LCM procedures is displayed in (A). Frozen liver sections from control, BDL, BDL-SMCC, and BDL-LGCC mice were sectioned with a cryostat and affixed the membrane side of nuclease and human nucleic acid free 2.0-mm PEN membrane slides. An LCM system (LMD7000; Leica, Buffalo Grove, IL) was then used to capture desmin-positive HSCs and collect them in a thin-walled PCR tube. Collected cells were then used to isolate RNA with the Arcturus Pico Pure RNA Isolation Kit (ThermoFisher Scientific, Waltham, MA), and realtime PCR analysis for cellular senescence markers p16, PAI-1, EGR1, and CCL2 were carried out. Enhanced expressions of p16 and EGR1 were discovered in isolated HSCs from BDL-SMCC mice liver when compared to control BDL groups (B), suggesting that SMCC cell therapy inhibited liver fibrosis through induction of cellular senescence in HSCs. *P < 0.05 versus normal or wild-type controls. # P < 0.05 versus control-BDL mice liver. (C) Formalin-fixed, paraffin-embedded liver sections from PSC patients were sectioned at 6 lm and affixed to the membrane side of PEN membrane slides. Sections were stained for desmin and an LCM system (LMD7000; Leica) was used to capture desmin-positive cells. Collected cells were used to extract RNA, as described above, and the senescence marker, PAI-1, and the inflammation marker, IL-8, were quantified with qPCR. *P < 0.05 versus normal. Abbreviation: qPCR, quantitative PCR.
in vivo emphasizes an essential role of this DE marker in mediating biliary regeneration and repair. This discovery also provides insight into the contribution of altered remodeling, epigenetic regulation, and senescence in recovering the severe liver injury.
Cholangiopathies cause morbidity and mortality and are the principal reason for liver transplantation. They are characterized by spotty, rather than diffuse, proliferation and loss of cholangiocytes lining differentsized bile ducts. The elucidation of the intracellular mechanisms regulating the differential regenerative responses of small and large cholangiocytes to cholestasis and liver injury/toxins will play a pivotal role in the development of therapeutic strategies for treatment of liver diseases (e.g., PBC, PSC, and cholangiocarcinoma). These cholangiopathies represent a serious public health concern because of the lack of novel therapeutic approaches, and this subsequently results in liver transplantation or mortality. (2, 24) During chronic hepatobiliary injury, a population of bipotent LPCs becomes activated to regenerate both cholangiocytes and hepatocytes. (25, 26) Cholangiocytes and hepatocytes share embryological origins, and this common heritage contributes to traits carried into adulthood. (27, 28) If small cholangiocytes with multipotential capacity exist within human and rodent bile ducts, these cells should also possess the ability to differentiate into either large cholangiocytes or hepatocytes during liver damage, such as diseased conditions in which large cholangiocytes or hepatocytes are lost or regenerative mechanisms are hampered. The plasticity of intrahepatic cholangiocytes and hepatocytes has been postulated that terminally differentiated cells of one lineage may directly differentiate into another lineage or undergo transdifferentiation. However, the data are interpretable also as expansion and differentiation of a progenitor's population. (29) Recent studies have demonstrated that meticulously isolated and rigorously characterized gallbladder epithelial cells cultured under defined in vitro conditions acquire hepatocyte-like properties, such as the ability to synthesize bile acids and take up low-density lipoprotein, without expression of markers of oval cells or hematopoietic progenitor cells. The recent discovery of biliary pluripotent cell populations provides for an alternative mechanism for expansion and differentiation of certain subpopulations of cholangiocytes as opposed to transdifferentiation.
(1) Therefore, specific subpopulations of cells, such as small cholangiocytes, that express known biliary progenitor cell markers, can be hypothesized to contain a multipotent cell population when exposed to certain pathological conditions. Our studies have suggested that such cells could attain functional pluripotent characteristics under the condition that large cholangiocytes are damaged or lost, and subsequently, they could be used to repopulate damaged bile ducts and livers. (6, 7) DNA methylation is an important epigenetic modification that can regulate gene expression and is tightly regulated by at least three DNMTs (DNMT1, DNMT3A, and DNMT3B). Aberrant DNA methylation has been implicated in many human diseases, including primary biliary disorders. (30) Intrahepatic accumulation of toxic bile acids and excretion products causes cellular injury. Recent developments indicate that accumulation of toxic bile acids induces epigenetic alterations, particularly acetylation, methylation of histones, and hypo-and hypermethylation of DNA. This has created a renewed interest in biliary pathogenesis and is providing novel insight into actions of bile acids at the nucleosomal level in relation to gene expression and pathophysiological consequences. Although DNA methylation has been tightly linked to liver injuries and poor disease outcome in many hepatic disorders, including human PBC, its application to progenitor phenotype-related mRNA expression is novel. A better understanding of how specific DNMTs contribute to aberrant mRNA expression will clearly advance the field and increase the knowledge of the mechanisms regulating the pathogenesis of cholestasis.
DNA methylation regulated by TGF-b activation has been demonstrated during chronic liver injury and malignant transformation. There is ample evidence for increased TGF-b activation in cholestatic liver injury. (11, 31) Analysis of the transcriptional changes that accompany the process of biliary differentiation has identified several inter-related signaling pathways that are critical during bile duct differentiation in vitro. (32) The molecule at the apex of these signaling pathways is BMP1, an astacin metalloproteinase. We demonstrated that BMP1 and Notch1 are up-regulated in human PSC and PBC samples. BMP1 cleaves procollagen and allows the triple helix of collagen to form in the ECM. Therefore, BMP1 may play a prominent role in the remodeling of the ECM surrounding the developing bile ducts. Interestingly, BMP1 is downregulated when biliary progenitor cells are cued to differentiate toward mature cholangiocytes. (33) Transient inhibition of the constitutive BMP pathway, either alone or in combination with TGF-b inhibition, is critical to the downstream effector, FoxA2, signaling in stem cell cultures. The observation that a number of BMP and TGF-b responsive genes (such as FoxA2) are activated during bile duct differentiation in vitro suggests their essential roles in the formation of biliary structures.
Hepatobiliary regeneration is critical for recovery of cholestatic liver diseases, such as PSC and PBC. Accumulation of senescent hepatobiliary cells, which are insensitive to mitotic stimuli, may impair the reserve for hepatobiliary regeneration. In addition, the association between increased hepatobiliary nuclear area and hepatobiliary dysfunction suggests that senescent cholangiocytes/hepatocytes may not function as normal mature cholangiocytes/hepatocytes. That is why our cultured small cholangiocytes behave differently than total liver shown in the MDR2 -/-and PSC patient samples. There is also an association between senescence measured as increased expression of senescent markers in cholangiocytes and hepatocytes and impaired liver synthetic function (increasing prothrombin time and decreasing serum albumin level). Thus, accumulation of senescent cholangiocytes/hepatocytes may contribute to loss of functional hepatobiliary mass, with sufficient accumulation of such cells eventually leading to hepatobiliary decompensation and liverrelated death, accounting for the strong link between cholangiocyte/hepatocyte senescent markers and adverse liver-related outcome. During clinical and biochemical dysfunction with progressive cholestatic liver disease, up to 87% of hepatobiliary cells in cholestatic liver diseases (CLDs) expressed senescence markers and may have impaired function. However, senescence of activated stellate cells limits liver fibrosis through reduced secretion of ECM components, enhanced secretion of ECM-degrading enzymes, and enhanced immune surveillance. The discovery of an association between reduced hepatic/enhanced hepatic stellate cellular senescence and FoxA2, a DE maker of liver development and recovery in CLD in particular, suggests an important translational mechanism in CLD development, progression, and recovery.
In conclusion, we have demonstrated epigenetic regulation of FoxA2 expression during cholestatic liver injury. Additionally, we have shown that expression of downstream anticellular senescence/fibrosis signaling of biliary regrowth/repair could be modulated by FoxA2. This indicates that therapeutic strategies to increase FoxA2 may be potentially useful to rebuild the hepatobiliary system after liver injury. Further work is warranted to evaluate the functional role of FoxA2 and the identified downstream targets and develop therapeutic strategies by taking advantage of FoxA2 overexpression in vivo. The ability to therapeutically manipulate mRNA expression is also feasible, and recent proof-of-concept studies have shown that mRNA agonists targeted to the liver can modulate expression of downstream genes. Moreover, aberrantly expressed mRNAs of FoxA2 and other DE markers may be useful to establish a diagnosis and for assessing prognosis in liver injury. Knowledge of specific processes, such as biliary proliferation, senescence, remodeling, and mesenchymal transition, that are regulated by FoxA2, and the identification of critical targets for such DE markers, provides novel insights into the mechanisms in development and recovery of the intrahepatic biliary epithelium and hepatic function after chronic liver injury.
